Issues related to diagnostic testing, Oncology, Hepatitis C funding H.R.7352/S.4875, the Pioneering Antimicrobial Subscriptions To End Upsurging Resistence Act of 2026 (PASTEUR Act) S.1941, the Cure Hepatitis C Act of 2025
2026 · 3rd Quarter (July 1 - Sep 30)
DH DIAGNOSTICS, LLC
Filed by DH DIAGNOSTICS LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- Not reported
- Expenses
- $310,000.00
- Registrant
- DH DIAGNOSTICS LLC
- Client
- DH DIAGNOSTICS, LLC
- Filing UUID
- 77f26974-8802-4fab-adf4-06f17f18bfd1
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues related to diagnostic testing, Oncology and the Reforming and Enhancing Sustainable Updates to Laboratory Services (the RESULTS Act, S.2761/H.R. 5269). S.1399/H.R.6197, the Health Tech Investment Act S.3287/H.R.6130, Alzheimer's Screening and Prevention (ASAP) Act
Literal federal measure citations: S.2761, H.R. 5269, S.1399, H.R.6197, S.3287, H.R.6130
Funding for diagnostics
Medical device supply-chain resilience, including semiconductor and memory-chip availability.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.